2019 October: RECENT PUBLICATIONS

Liver imaging

  • Drug Metab Pharmacokinet. 2019;S1347-4367(18)30152-6. Quantitative investigation of hepatobiliary transport of [11C]telmisartan in humans by PET imaging. Maeda K, Ohnishi A, Sasaki M, Ikari Y, Aita K, Watanabe Y, Kusuhara H, Sugiyama Y, Senda M. PubMed
  • Drug Metab Pharmacokinet. 2019;S1347-4367(19)30033-3. Evaluation of transporter-mediated hepatobiliary transport of newly developed 18F-labeled pitavastatin derivative, PTV-F1, in rats by PET imaging. Kimura H, Yagi Y, Mikamo M, Maeda K, Kagawa S, Arimitsu K, Higashi T, Nishii R, Ono M, Nakamoto Y, Togashi K, Kusuhara H, Saji H. PubMed
  • Nucl Med Biol. 2019;74-75:25-31. Evaluation of [18F]pitavastatin as a positron emission tomography tracer for in vivo organic transporter polypeptide function. Yagi Y, Kimura H, Okuda H, Ono M, Nakamoto Y, Togashi K, Saji H. PubMed
  • Eur Radiol. 2019;in press. Consensus report from the 8th international forum for liver Magnetic Resonance Imaging. Zech CJ, Ba-Ssalamah A, Berg T, Chandarana H, Chau GY, Grazioli L, Kim MJ, Lee JM, Merkle EM, Murakami, Ricke J, B Sirlin C, Song B, Taouli B, Yoshimitsu K, Koh DM. PubMed
  • Eur Radiol. 2019;In press. Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Beer L, Mandorfer M, Bastati N, Poetter-Lang S, Tamandl D, Stoyanova DP, Elmer MC, Semmler G, Simbrunner B, Hodge JC, Sirlin CB, Reiberger T, Ba-Ssalamah A. PubMed

Atorvastatin in patients with hypercholesterolemia

  • Drug Metab Pharmacokinet. 2019;S1347-4367(19)30068-0. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. Lee N, Maeda K, Fukizawa S, Ieiri I, Tomaru A, Akao H, Takeda K, Iwadare M, Niwa O, Masauji T, Yamane N, Kajinami K, Kusuhara H, Sugiyama Y. PubMed

P-gp and fluorescent substrate of cyclosporin

  • Drug Metab Dispos. 2019;47:1013-1023. Synthesis and characterization of Bodipy-FL-Cyclosporine A as a substrate for multidrug resistance-linked P-Glycoprotein (ABCB1). Sajid A, Raju N, Lusvarghi S, Vahedi S, Swenson RE, Ambudkar SV. PubMed

Herb-drug interactions with drug transporters

  • Drug Metab Dispos. 2019;47:1040-1049. Rhinacanthin-C mediated herb-drug interactions with drug transporters and phase I drug-metabolizing enzymes. Dunkoksung W, Vardhanabhuti N, Siripong P, Jianmongkol S. PubMed

Kp,uu prediction

  • Drug Metab Dispos. 2019;47:1050-1060. Prediction of tissue-plasma partition coefficients using microsomal partitioning: Incorporation into Physiologically based Pharmacokinetic Models and steady-state volume of distribution predictions. Holt K, Ye M, Nagar S, Korzekwa K. PubMed

Diclofenac distribution in KO mice

  • Drug Metab Dispos. 2019;47:1080-1092. Identification and characterization of efflux transporters that modulate the subtoxic disposition of Diclofenac and its metabolites. Scialis RJ, Aleksunes LM, Csanaky IL, Klaassen CD, Manautou JE. PubMed

Cell cultures and transporters

  • Drug Metab Dispos. 2019;47:1222-1230. Optimization of canalicular ABC transporter function in HuH-7 cells by modification of culture conditions. Kang HE, Malinen MM, Saran C, Honkakoski P, Brouwer KLR. PubMed

Function of OATP1B3-1B7

  • Am J Physiol. 2019;in press. OATP1B3-1B7 a novel Organic Anion Transporting Polypeptide is modulated by FXR ligands and transports bile acids. Malagnino V, Hussner J, Issa A, Midzic A, Meyer Zu Schwabedissen HE. PubMed
  • Mol Pharmacol. 2019;96:128-137. OATP1B3-1B7 (LST-3TM12) is a drug transporter that affects endoplasmic reticulum access and the metabolism of Ezetimibe. Malagnino V, Duthaler U, Seibert I, Krähenbühl S, Meyer Zu Schwabedissen HE. PubMed

Drug-induced cholestasis

  • Arch Toxicol. 2019;93:1169-1186. Mechanisms and in vitro models of drug-induced cholestasis. Gijbels E, Vilas-Boas V, Deferm N, Devisscher L, Jaeschke H, Annaert P, Vinken M. PubMed
  • Methods Mol Biol. 2019;1981:55-73. Vesicle- and hepatocyte-based assays for identification of drug candidates inhibiting BSEP function. Van Brantegem P, Deferm N, Qi B, De Vocht T, Annaert P. PubMed
  • Methods Mol Biol. 2019;1981:335-350. Detection of drug-induced cholestasis potential in Sandwich-Cultured Human Hepatocytes. Deferm N, Richert L, Van Brantegem P, De Vocht T, Qi B, de Witte P, Bouillon T, Annaert P. PubMed

Drug protein binding and hepatic clearance

  • Drug Metab Dispos. 2019;in press. Protein binding and hepatic clearance: Re-examining the discrimination between models of hepatic clearance with diazepam in the isolated perfused rat liver preparation. Wang HJ, Benet LZ. PubMed
  • Drug Metab Dispos. 2019;47:1307-1313. Investigating the impact of albumin on the liver uptake of Pitavastatin and Warfarin in Nagase analbuminemic rats. Chang JH, Chen YC, Cheong J, Jones RS, Pang J. PubMed

Transporters and drug pharmacokinetics

  • AAPS J. 2019;21:103. How transporters have changed basic pharmacokinetic understanding. Benet LZ, Bowman CM, Sodhi JK. PubMed
  • Mol Pharmacol. 2019;95:490-506. Organic Anion Transporting Polypeptides: Emerging roles in cancer pharmacology. Schulte RR, Ho RH. PubMed

Transporters and pharmacogenomics

  • Pulm Pharmacol Ther. 2019;57:101809. Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes. Poller B, Woessner R, Barve A, Tillmann HC, Vemula J, Nica A, Elbast W, Schiller H, End P, Camenisch G, Weiss M. PubMed

Transporters and chronic kidney disease

  • Clin Pharmacol Ther. 2019;106:792-802. Effect of hepatic Organic Anion-Transporting Polypeptide 1B inhibition and Chronic Kidney Disease on the pharmacokinetics of a liver-targeted Glucokinase activator: A model-based evaluation. Bergman A, Bi YA, Mathialagan S, Litchfield J, Kazierad DJ, Pfefferkorn JA, Varma MVS. PubMed

Systemic treatment of liver cancer

  • Clin Pharmacol Ther. 2019; in press. Sorafenib activity and disposition in liver cancer does not depend on Organic Cation Transporter 1. Chen M, Neul C, Schaeffeler E, Frisch F, Winter S, Schwab M, Koepsell H, Hu S, Laufer S, Baker SD, Sparreboom A, Nies AT. PubMed
  • Clin Liver Dis (Hoboken). 2019;14:56-61. New drugs effective in the systemic treatment of hepatocellular carcinoma. Montironi C, Montal R, Llovet JM. PubMed
  • Clin Liver Dis (Hoboken). 2019;14:62-65. Mechanisms of action of drugs effective in hepatocellular carcinoma. Sarcognato S, García-Lezana T, Villanueva A. PubMed